Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

ALK-Abello’s Pharmalgen Wins U.K. Cost-Agency Backing for Stings

ALK-Abello A/S’s Pharmalgen won the preliminary backing of the U.K.’s health-cost agency for the treatment of severe reactions to bee and wasp stings.

As many as nine people die every year in the U.K. from allergic reactions, known as anaphylaxis, to the stings, the National Institute for Health and Clinical Excellence said in an e-mailed statement. Pharmalgen, an injection, prevents the reaction by desensitizing the immune system, said the agency, known as NICE.

A final decision probably will be made by February, NICE said. ALK-Abello is based in Hoersholm, Denmark.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.